- Home
- Therapeutics Development Services
- Small Molecule PARPi Development Services
Poly(ADP-ribose) polymerase (PARP) inhibitors, commonly known as PARPi, have emerged as a promising class of small molecule therapeutics with the potential to revolutionize the treatment of a wide range of diseases. At Alfa Cytology, we provides small molecule PARP inhibitor development services for combating various diseases.
PARP enzymes play a vital role in various cellular processes, including DNA repair, gene expression, and cell signaling. When PARP activity is inhibited, the ability of cells to effectively repair DNA damage is compromised, leading to cell death, particularly in cells with pre-existing DNA repair deficiencies. This vulnerability has been extensively exploited in the treatment of cancers, where PARPi have demonstrated remarkable efficacy, especially in tumors with BRCA1/2 mutations or other homologous recombination deficiencies.
Fig. 1 PARP-1 hyperactivation as an aggravating factor in the development of various diseases. (Maluchenko N.V., et al. 2021)
Beyond oncology, the therapeutic potential of PARPi extends to a diverse array of other diseases. Emerging evidence suggests that these small molecule inhibitors may hold promise in the management of neurodegenerative disorders, autoimmune conditions, and even metabolic diseases. By targeting the underlying mechanisms that contribute to disease pathogenesis, PARPi offer the potential for more targeted and effective treatment approaches.
| NCT | PARP Inhibitor | Disease | Phase |
| NCT02326844 | BMN 673 | Ovarian Cancer | |
| NCT05332561 | Olaparib | Breast Cancer | |
| NCT04511039 | Talazoparib | Colorectal Cancer | |
| NCT03026881 | Fluzoparib | Gastroesophageal Adenocarcinoma | |
| NCT04410887 | Olaparib | Gastric Cancer | |
| NCT01489865 | Veliparib | Pancreatic Cancer | |
| NCT03062397 | JPI - 289 | Acute Ischemic Stroke |
At Alfa Cytology, our team of highly skilled biological specialists offers a comprehensive range of services to support the development of small molecule PARP inhibitors for various diseases. Our state-of-the-art facilities and multidisciplinary team of experts provide comprehensive services to support the entire drug development process, from target identification and validation to preclinical studies and biomarker development.
High-Selective Inhibitor Development
Hit Identification
Identifying and validating small molecules that interact with PARP.
Hit to lead
Optimizing hit compounds to enhance their potency and pharmacological properties.
Lead Optimization
Refining lead compounds to improve their drug-like characteristics and effectiveness.
Preclinical research
Evaluating the candidate molecule's safety, efficacy, and pharmacological profile.
Alfa Cytology provides development services for small molecule PARP inhibitors, covering drug design, screening, and efficacy research to find ideal drug candidates for you and accelerate preclinical research on your therapeutics development. To learn more about our capabilities in small molecule PARP inhibitor development or to discuss potential collaborative opportunities, please don't hesitate to contact us.
References
For research use only. Not intended for any clinical use.